Exhibit 99.1

NEOFORMA REPORTS THIRD QUARTER 2003 FINANCIAL RESULTS

Company generates $6.0 million in total cash flow during the quarter

SAN JOSE, CA – October 21, 2003 – Neoforma, Inc. (Nasdaq: NEOF), a leading provider of Web-based supply chain management solutions for the healthcare industry, generated revenue of $2.9 million on a generally accepted accounting principles (GAAP) basis in the third quarter ended September 30, 2003, an increase over the $1.4 million reported in the same quarter of 2002. Neoforma generated adjusted revenue of $20.5 million in the third quarter of 2003, excluding the impact of Emerging Issues Task Force Abstract No. 01-9 (EITF No. 01-9), an increase from the $20.1 million reported in the same quarter in the prior year.

In accordance with GAAP, for the third quarter of 2003, Neoforma’s net loss and net loss per share equaled $15.6 million and $0.85, respectively, representing an improvement over the $21.1 million net loss and $1.24 net loss per share in the third quarter of 2002. Adjusted net income and net income per share for the third quarter of 2003 were $5.6 million and $0.30 per share, respectively, as compared to the $5.3 million and $0.31, respectively, recorded in the third quarter of 2002.

Neoforma’s adjusted financial information, which is not in accordance with GAAP, excludes the application of EITF No. 01-9 and certain expenses, gains and losses. Adjusted financial information serves as a measure of the performance of Neoforma’s ongoing core operations. A description of the adjusted financial information for the periods presented and reconciliation of these results to GAAP financial information are included in the attached financial statements and available in the investor relations section of Neoforma’s Web site at http://investor.neoforma.com.

“Neoforma helps the healthcare supply chain operate more efficiently by automating our customers’ manual processes and facilitating collaboration between hospitals, manufacturers, distributors and group purchasing organizations,” says Bob Zollars, chairman and chief executive officer. “Using Neoforma’s easy-to-deploy solutions, our customers can turn data into actionable information, which provides immediate value. In the third quarter, we continued to measure and document this value with our customers.”

Third Quarter 2003 Highlights

Neoforma made significant operational and strategic progress during the third quarter. During the quarter, the Company:

• Amended the outsourcing and operating agreement with Novation, VHA Inc. and University HealthSystem Consortium (UHC) to simplify the basis on which Neoforma earns fees from Novation,

increase Neoforma’s responsibility for managing relationships with suppliers and clarify the rights to data collected by Neoforma’s solutions;

• Continued the diversification of Neoforma’s revenue streams;

• Made wireless technology available as part of Neoforma Materials Management Solution^™;

• Entered into an agreement with McKesson Information Solutions to develop certified integration between Neoforma’s and McKesson’s complementary supply chain management technologies;

• Signed a definitive asset purchase agreement to acquire substantially all the assets of I-many, Inc.’s Health & Life Sciences business;

• Brought additional financial expertise to the board of directors with the appointment of Wayne B. Lowell to the board and its audit and compensation committees; and

• Supported $2.2 billion in marketplace volume.

Third Quarter 2003 Financial Results

For the third quarter ended September 30, 2003, on a GAAP basis, Neoforma’s $2.9 million in total revenue consisted of $1.0 million in Marketplace revenue and $1.9 million in Trading Partner Services revenue. Marketplace revenue and Trading Partner Services revenue increased from the $0.2 million and $1.2 million, respectively, recorded in the same quarter in the prior year.

On an adjusted basis, excluding the application of EITF No. 01-9, Neoforma’s revenue for the third quarter was $20.5 million, comprised of $18.3 million in Marketplace revenue and $2.1 million in Trading Partner Services revenue. Adjusted Marketplace revenue decreased from the $18.7 million recorded in the third quarter of 2002, due to a decline of approximately $1.2 million in related party revenue as a result of a scheduled reduction in the quarterly maximum payment under the Company’s outsourcing and operating agreement with Novation, VHA and UHC. This decline was partially offset by a $768,000 increase in revenue from suppliers, related to their utilization of Neoforma’s order and contract management solutions, over the same period. Trading Partner Services revenue increased from the $1.4 million recorded in the same period in the prior year, primarily due to increases in revenue from Neoforma’s data management and materials management solutions.

During the third quarter, Neoforma continued to diversify its revenue streams. The Company generated more than 15% of its adjusted revenue from sources other than Novation, up from 14% in the second quarter of 2003 and 7% in the third quarter of 2002.

Neoforma classifies non-cash amortization of partnership costs as an offset against related party revenue under EITF No. 01-9, which became effective for the Company in January 2002. This accounting treatment has no impact on the Company’s loss from operations, net loss, net loss per share or total cash flow because the reductions to operating expenses and revenue are equal.

In the third quarter, Neoforma’s total GAAP operating expenses were $18.3 million, an improvement over the $22.3 million in the third quarter of 2002. Adjusted operating expenses were $14.7 million in the third quarter, a slight increase from the $14.6 million in the same quarter in the previous year.

On a GAAP basis, Neoforma reported a loss from operations of $15.4 million in the third quarter, improving significantly over the $20.9 million loss in the third quarter of 2002. During the quarter, Neoforma achieved $5.8 million in EBITDA, an increase from the $5.5 million achieved in the same quarter in the prior year.

As of September 30, 2003, Neoforma’s cash, cash equivalents and short-term investments totaled $28.0 million. During the quarter, total cash flow equaled $6.0 million and free cash flow equaled $5.3 million. Free cash flow is calculated as net cash used in operating activities plus amortization of partnership costs offset against related party revenue, minus purchases of property and equipment.

During the third quarter, Neoforma’s total and free cash flow included $18.0 million received from Novation under the outsourcing and operating agreement, of which $17.3 million was recognized as related party revenue and $700,000 was deferred. During the fourth quarter, Neoforma expects to recognize $17.3 million in related party revenue, consisting of $15.2 million in cash from Novation and recognition of a total of $2.1 million in revenue that was deferred during the first nine months of the year.

“Neoforma generated strong cash flow during the quarter, and we will manage our cash prudently as we continue to build Neoforma for the long term,” says Andrew Guggenhime, chief financial officer.

About Neoforma

Neoforma is a leading supply chain management solutions provider for the healthcare industry. Through a unique combination of technology, information and services, Neoforma provides innovative solutions to over 1,450 hospitals and suppliers, supporting more than $8 billion in annualized transaction volume. By bringing together contract information and order data, Neoforma’s integrated solution set delivers a comprehensive view of an organization’s supply chain, driving significant cost savings and better decision-making for both hospitals and suppliers. For more information, point your browser to http://www.neoforma.com.

###

This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include statements related to Neoforma’s leadership position, Neoforma helping the healthcare supply chain operate more efficiently, our customers’ ability to turn data into actionable information, thus providing immediate value, the anticipated purchase of certain I-many, Inc. assets and the continued diversification of Neoforma’s revenue streams. There are a number of risks that could cause actual results to differ materially from those anticipated by these forward-looking statements. These risks include the willingness of hospitals and suppliers to accept Neoforma’s business model of providing supply chain management solutions for the healthcare industry, risks related to pending acquisitions and the ability of Neoforma to manage its growth and related technological challenges. These risks and other risks are described in Neoforma’s periodic reports filed with the SEC, including its Form 10-K for the year 2002 and its Form 10-Q for the quarter ended June 30, 2003. These statements are current as of the date of this release and Neoforma assumes no obligation to update the forward-looking information contained in this news release.

Neoforma is a trademark of Neoforma, Inc. Other Neoforma logos, product names and service names are also trademarks of Neoforma, Inc., which may be registered in other countries. Other product and brand names are trademarks of their respective owners.

Contacts:

Rebecca Oles, Neoforma, media, 408.468.4363, rebecca.oles@neoforma.com

Amanda Mogin, Neoforma, investors, 408.468.4251, amanda.mogin@neoforma.com

John Snyder, for Neoforma, investors, 206.262.0291, john@snyderir.com

NEOFORMA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

(unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2002			2003			2002			2003
REVENUE:
Marketplace revenue:
Related party, net of amortization of partnership costs of $18,452, $17,300, $49,355 and $51,603 for the three months ended September 30, 2002 and 2003, and for the nine months ended September 30, 2002 and 2003, respectively.	$	—		$	—		$	—		$	297
Other		248			1,016			737			2,371
Total Marketplace revenue		248			1,016			737			2,668
Trading Partner Services revenue		1,180			1,896			1,884			5,365
Total revenue		1,428			2,912			2,621			8,033
OPERATING EXPENSES:
Cost of services		2,312			1,895			6,475			4,754
Operations		6,459			4,947			13,305			14,888
Product development		4,381			4,451			12,120			13,377
Selling and marketing		3,095			4,648			9,391			14,258
General and administrative		3,583			2,242			11,283			8,339
Amortization of intangibles		32			147			32			441
Amortization of partnership costs		1,290			14			8,936			847
Write-off of purchased software		6			—			250			—
Write-off of acquired in-process research and development		110			—			110			—
Restructuring		—			—			(68	)		—
Write-down of non-marketable investments, net		—			—			(184	)		—
Write-down of note receivable		1,053			—			1,053			—
Loss on divested business		—			—			59			—
Total operating expenses		22,321			18,344			62,762			56,904
Loss from operations		(20,893	)		(15,432	)		(60,141	)		(48,871	)
OTHER EXPENSE		(225	)		(202	)		(537	)		(762	)
Net loss	$	(21,118	)	$	(15,634	)	$	(60,678	)	$	(49,633	)
NET LOSS PER SHARE:
Basic and diluted	$	(1.24	)	$	(0.85	)	$	(3.65	)	$	(2.76	)
Weighted average shares — basic and diluted		16,985			18,445			16,623			17,990

In addition to our consolidated financial statements presented in accordance with GAAP, Neoforma, Inc. uses non-GAAP, or adjusted, measures of operating results, net income and net income per share, which are adjusted from results based on GAAP to exclude the application of EITF No. 01-9 and certain expenses, gains and losses. Neoforma management believes that the non-GAAP adjusted results provide added insight into the Company's performance by focusing on results generated by the Company's ongoing core operations. Neoforma management uses the non-GAAP adjusted results when assessing the performance of its ongoing core operations, in making resource allocation decisions and for planning and forecasting. Additionally, incentive compensation for the Company, including management, is based on results on this basis. In addition, because we historically have reported adjusted results, we believe the inclusion of comparative numbers provides consistency in our financial reporting. The non-GAAP financial measures should be considered in addition to, not as a substitute for, or superior to, the measures of financial performance prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measures.

NEOFORMA, INC.

ADJUSTED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (1)

(in thousands, except per share amounts)

(unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2002			2003			2002			2003
REVENUE:
Marketplace revenue:
Related party	$	18,452		$	17,300		$	49,355		$	51,900
Other		248			1,016			737			2,371
Total adjusted marketplace revenue		18,700			18,316			50,092			54,271
Trading partner services revenue		1,353			2,135			2,343			5,832
Total adjusted revenue		20,053			20,451			52,435			60,103
OPERATING EXPENSES:
Cost of services		1,986			1,744			5,448			4,301
Operations		3,581			2,638			9,174			7,199
Product development		3,730			4,068			10,065			12,066
Selling and marketing		2,545			4,244			7,545			12,930
General and administrative		2,731			1,999			7,631			6,852
Adjusted operating expenses		14,573			14,693			39,863			43,348
EBITDA		5,480			5,758			12,572			16,755
OTHER EXPENSE		(225	)		(202	)		(537	)		(762	)
Adjusted net income	$	5,255		$	5,556		$	12,035		$	15,993
ADJUSTED NET INCOME PER SHARE:
Basic	$	0.31		$	0.30		$	0.72		$	0.89
Weighted average shares — basic		16,985			18,445			16,623			17,990

(1) These adjusted condensed consolidated statements of operations exclude the impact of EITF No. 01-9 and certain expenses, gains and losses. Under EITF No. 01-9, the Company offsets non-cash amortization of partnership costs against related party revenue in an amount equal to the lesser of the two in any period. Any amortization of partnership costs in excess of related party revenue in any period is classified as an operating expense. As a result of the adoption of EITF No. 01-9, the Company offset approximately $18,625, $17,539, $49,814 and $52,070 of amortization of partnership costs against related party revenue in its GAAP condensed consolidated statements of operations for the three months ended September 30, 2002 and 2003, and for the nine months ended September 30, 2002 and 2003, respectively. As reclassifications, the application of EITF No. 01-9 had no impact on loss from operations, net loss or net loss per share. The excluded expenses, gains and losses consisted of depreciation, amortization of intangibles, amortization of deferred compensation, amortization of partnership costs, write-off of purchased software, write-off of acquired in-process research and development, restructuring, write-down of non-marketable investments, net, write-down of note receivable and loss on divested business.

NEOFORMA, INC.

RECONCILIATION OF ADJUSTED CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS TO GAAP

(in thousands, except per share amounts)

(unaudited)

	Three Months Ended September 30, 2003
	Adjusted Results			Excluded Expenses, Gains and Losses			Application of EITF No. 01-9			GAAP Allocations						GAAP Results As Reported
										Depreciation			Amortization of Deferred Compensation
REVENUE:
Marketplace revenue:
Related party	$	17,300		$	—		$	(17,300	)	$	—		$	—		$	—
Other		1,016			—			—			—			—			1,016
Total Marketplace revenue		18,316			—			(17,300	)		—			—			1,016
Trading Partner Services revenue		2,135			—			(239	)		—			—			1,896
Total revenue		20,451			—			(17,539	)		—			—			2,912
OPERATING EXPENSES:
Cost of services		1,744			—			—			126			25			1,895
Operations		2,638			—			—			2,299			10			4,947
Product development		4,068			—			—			324			59			4,451
Selling and marketing		4,244			—			—			312			92			4,648
General and administrative		1,999			—			—			185			58			2,242
Adjusted operating expenses		14,693
EBITDA		5,758
Depreciation		—			3,246			—			(3,246	)		—			—
Amortization of intangibles		—			147			—			—			—			147
Amortization of deferred compensation		—			244			—			—			(244	)		—
Amortization of partnership costs		—			17,553			(17,539	)		—			—			14
Total operating expenses					21,190			(17,539	)		—			—			18,344
Loss from operations					(21,190	)		—			—			—			(15,432	)
OTHER EXPENSE		(202	)		—			—			—			—			(202	)
Net income (loss)	$	5,556		$	(21,190	)	$	—		$	—		$	—		$	(15,634	)
NET INCOME (LOSS) PER SHARE:
Basic	$	0.30														$	(0.85	)
Weighted average shares—basic		18,445															18,445
	Three Months Ended September 30, 2002
	Adjusted Results			Excluded Expenses, Gains and Losses			Application of EITF No. 01-9			GAAP Allocations						GAAP Results As Reported
										Depreciation			Amortization of Deferred Compensation
REVENUE:
Marketplace revenue:
Related party	$	18,452		$	—		$	(18,452	)	$	—		$	—		$	—
Other		248			—			—			—			—			248
Total Marketplace revenue		18,700			—			(18,452	)		—			—			248
Trading Partner Services revenue		1,353			—			(173	)		—			—			1,180
Total revenue		20,053			—			(18,625	)		—			—			1,428
OPERATING EXPENSES:
Cost of services		1,986			—			—			248			78			2,312
Operations		3,581			—			—			2,788			90			6,459
Product development		3,730			—			—			472			179			4,381
Selling and marketing		2,545			—			—			271			279			3,095
General and administrative		2,731			—			—			255			597			3,583
Adjusted operating expenses		14,573
EBITDA		5,480
Depreciation		—			4,034			—			(4,034	)		—			—
Amortization of intangibles		—			32			—			—			—			32
Amortization of deferred compensation		—			1,223			—			—			(1,223	)		—
Amortization of partnership costs		—			19,915			(18,625	)		—			—			1,290
Write-off of purchased software		—			6			—			—			—			6
Write-off of acquired in-process research and development		—			110			—			—			—			110
Write-down of note receivable		—			1,053			—			—			—			1,053
Total operating expenses					26,373			(18,625	)		—			—			22,321
Loss from operations					(26,373	)		—			—			—			(20,893	)
OTHER EXPENSE		(225	)		—			—			—			—			(225	)
Net income (loss)	$	5,255		$	(26,373	)	$	—		$	—		$	—		$	(21,118	)
NET INCOME (LOSS) PER SHARE:
Basic	$	0.31														$	(1.24	)
Weighted average shares—basic		16,985															16,985

NEOFORMA, INC.

RECONCILIATION OF ADJUSTED CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS TO GAAP

(in thousands, except per share amounts)

(unaudited)

	Nine Months Ended September 30, 2003
	Adjusted Results			Excluded Expenses, Gains and Losses			Application of EITF No. 01-9			GAAP Allocations						GAAP Results As Reported
										Depreciation			Amortization of Deferred Compensation
REVENUE:
Marketplace revenue:
Related party	$	51,900		$	—		$	(51,603	)	$	—		$	—		$	297
Other		2,371			—			—			—			—			2,371
Total Marketplace revenue		54,271			—			(51,603	)		—			—			2,668
Trading Partner Services revenue		5,832			—			(467	)		—			—			5,365
Total revenue		60,103			—			(52,070	)		—			—			8,033
OPERATING EXPENSES:
Cost of services		4,301			—			—			336			117			4,754
Operations		7,199			—			—			7,540			149			14,888
Product development		12,066			—			—			995			316			13,377
Selling and marketing		12,930			—			—			896			432			14,258
General and administrative		6,852			—			—			540			947			8,339
Adjusted operating expenses		43,348
EBITDA		16,755
Depreciation		—			10,307			—			(10,307	)		—			—
Amortization of intangibles		—			441			—			—			—			441
Amortization of deferred compensation		—			1,961			—			—			(1,961	)		—
Amortization of partnership costs		—			52,917			(52,070	)		—			—			847
Total operating expenses					65,626			(52,070	)		—			—			56,904
Loss from operations					(65,626	)		—			—			—			(48,871	)
OTHER EXPENSE		(762	)		—			—			—			—			(762	)
Net income (loss)	$	15,993		$	(65,626	)	$	—		$	—		$	—		$	(49,633	)
NET INCOME (LOSS) PER SHARE:
Basic	$	0.89														$	(2.76	)
Weighted average shares—basic		17,990															17,990
	Nine Months Ended September 30, 2002
	Adjusted Results			Excluded Expenses, Gains and Losses			Application of EITF No. 01-9			GAAP Allocations						GAAP Results As Reported
										Depreciation			Amortization of Deferred Compensation
REVENUE:
Marketplace revenue:
Related party	$	49,355		$	—		$	(49,355	)	$	—		$	—		$	—
Other		737			—			—			—			—			737
Total Marketplace revenue		50,092			—			(49,355	)		—			—			737
Trading Partner Services revenue		2,343			—			(459	)		—			—			1,884
Total revenue		52,435			—			(49,814	)		—			—			2,621
OPERATING EXPENSES:
Cost of services		5,448			—			—			811			216			6,475
Operations		9,174			—			—			3,875			256			13,305
Product development		10,065			—			—			1,529			526			12,120
Selling and marketing		7,545			—			—			944			902			9,391
General and administrative		7,631			—			—			888			2,764			11,283
Adjusted operating expenses		39,863
EBITDA		12,572
Depreciation		—			8,047			—			(8,047	)		—			—
Amortization of intangibles		—			32			—			—			—			32
Amortization of deferred compensation		—			4,664			—			—			(4,664	)		—
Amortization of partnership costs		—			58,750			(49,814	)		—			—			8,936
Write-off of purchased software		—			250			—			—			—			250
Write-off of acquired in-process research and development		—			110			—			—			—			110
Restructuring		—			(68	)		—			—			—			(68	)
Write-down of non-marketable investments, net		—			(184	)		—			—			—			(184	)
Write-down of note receivable		—			1,053			—			—			—			1,053
Loss on divested business		—			59			—			—			—			59
Total operating expenses					72,713			(49,814	)		—			—			62,762
Loss from operations					(72,713	)		—			—			—			(60,141	)
OTHER EXPENSE		(537	)		—			—			—			—			(537	)
Net income (loss)	$	12,035		$	(72,713	)	$	—		$	—		$	—		$	(60,678	)
NET INCOME (LOSS) PER SHARE:
Basic	$	0.72														$	(3.65	)
Weighted average shares—basic		16,623															16,623

NEOFORMA, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except per share amounts)

(unaudited)

ASSETS
	December 31, 2002			September 30, 2003
CURRENT ASSETS:
Cash and cash equivalents	$	23,277		$	26,519
Short-term investments		1,305			1,435
Accounts receivable, net of allowance for doubtful accounts		1,828			4,171
Related party accounts receivable		800			519
Prepaid expenses and other current assets		3,357			3,101
Total current assets		30,567			35,745
PROPERTY AND EQUIPMENT, net		16,821			9,800
INTANGIBLES, net of amortization		2,610			2,168
GOODWILL		1,414			1,414
CAPITALIZED PARTNERSHIP COSTS, net of amortization		166,451			120,691
NON-MARKETABLE INVESTMENTS		83			83
RESTRICTED CASH		1,020			1,020
OTHER ASSETS		1,844			1,839
Total assets	$	220,810		$	172,760
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Notes payable, current portion	$	4,000		$	393
Accounts payable		3,803			2,207
Accrued payroll		7,776			3,783
Other accrued liabilities		4,288			2,938
Deferred revenue, current portion		3,027			5,562
Total current liabilities		22,894			14,883
DEFERRED RENT		623			650
DEFERRED REVENUE, less current portion		1,689			473
OTHER LIABILITIES		105			—
ACCRUED INTEREST ON RELATED PARTY NOTES PAYABLE		2,516			245
NOTES PAYABLE, less current portion:
Due to related party		14,000			14,000
Other		152			46
Total notes payable, less current portion		14,152			14,046
STOCKHOLDERS’ EQUITY:
Common Stock $0.001 par value:
Authorized — 300,000 shares at September 30, 2003
Issued and outstanding: 17,691 and 18,645 shares at December 31, 2002 and September 30, 2003, respectively		18			19
Warrants		80			80
Additional paid-in capital		814,162			824,161
Notes receivable from stockholders		(6,460	)		(5,420	)
Deferred compensation		(2,649	)		(424	)
Unrealized loss on available-for-sale securities		—			—
Accumulated deficit		(626,320	)		(675,953	)
Total stockholders’ equity		178,831			142,463
Total liabilities and stockholders’ equity	$	220,810		$	172,760

NEOFORMA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

	Nine Months Ended September 30,
	2002			2003
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(60,678	)	$	(49,633	)
Adjustments to reconcile net loss to net cash used in operating activities:
Employee stock compensation		268			10
Provision for doubtful accounts		83			271
Depreciation and amortization of property and equipment		8,047			10,307
Write-off of purchased software		250			—
Amortization of intangibles		32			441
Amortization of partnership costs classified as an operating expense		8,936			847
Amortization of deferred compensation		4,664			1,961
Amortization of deferred debt costs		175			—
Write-off of in-process research and development		110			—
Write-down of note receivable		1,053			—
Loss on divested business		59			—
Accrued interest receivable on stockholder notes receivable		(54	)		(19	)
Change in assets and liabilities, net of divestitures:
Restricted cash		500			—
Accounts receivable		723			(2,333	)
Prepaid expenses and other current assets		(2,249	)		257
Other assets		1,156			5
Accounts payable		(648	)		(1,596	)
Accrued liabilities and accrued payroll		(314	)		(4,246	)
Deferred revenue		(198	)		1,319
Deferred rent		95			27
Accrued interest payable on related party notes payable		1,425			(2,271	)
Net cash used in operating activities		(36,565	)		(44,653	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of marketable investments		—			(2,789	)
Proceeds from the sale or maturity of marketable investments		—			2,659
Cash paid in connection with the acquisition of MedContrax, Inc. and Med-ecorp, Inc.		(1,494	)		—
Purchases of property and equipment		(2,097	)		(3,286	)
Net cash used in investing activities		(3,591	)		(3,416	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Amortization of partnership costs offset against related party revenue		49,814			52,070
Repayments of notes payable		(2,204	)		(3,713	)
Cash received related to options exercised		201			805
Proceeds from the issuance of common stock under the employee stock purchase plan		813			1,087
Common stock repurchased, net of notes receivable issued to common stockholders		—			(2	)
Collections of notes receivable from stockholders		16			1,064
Net cash provided by financing activities		48,640			51,311
Net increase in cash and cash equivalents		8,484			3,242
Cash and cash equivalents, beginning of period		14,096			23,277
Cash and cash equivalents, end of period	$	22,580		$	26,519